Favezelimab

BIOLOGICAL7 trials

Conditions

Advanced Non-Small Cell Lung CancerAdvanced tumorsHematologic malignanciesHodgkin DiseaseLymphoma, B-CellLymphoma, Non-HodgkinNeoplasm MetastasisNeoplasms

Phase 1

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

CompletedNCT02720068

Merck Sharp & Dohme LLCNeoplasms

Start: 2016-05-02End: 2024-03-15Updated: 2025-05-30

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

CompletedNCT03598608

Merck Sharp & Dohme LLCHodgkin Disease, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin

Start: 2018-10-17End: 2026-01-28Updated: 2026-02-05

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

CompletedCTIS2023-503587-17-00

Merck Sharp & Dohme LLCHematologic malignancies

Start: 2019-03-20End: 2025-10-09Target: 35Updated: 2025-09-18

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

WithdrawnNCT06395090

Merck Sharp & Dohme LLCNeoplasm Metastasis

Start: 2025-01-15End: 2029-06-30Updated: 2025-04-08

Phase 2

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

CompletedNCT03516981

Merck Sharp & Dohme LLCAdvanced Non-Small Cell Lung Cancer

Start: 2018-10-01End: 2025-06-13Updated: 2025-07-01

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

CompletedCTIS2022-500990-16-00

Merck Sharp & Dohme LLCStage IV non-small cell lung cancer

Start: 2018-12-19End: 2025-06-13Target: 84Updated: 2025-06-06

Phase 3

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

RecruitingCTIS2022-501254-10-00

Merck Sharp & Dohme LLCAdvanced tumors

Start: 2018-08-24Target: 1252Updated: 2025-11-17

2025-10-01

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

2025-02-271 citations

A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.

Journal of Clinical Oncology2024-06-012 citations

A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

Journal of Clinical Oncology2024-06-011 citations

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Blood2023-11-024 citations

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Blood2023-11-023 citations

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Blood2023-11-021 citations

3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff

Regular and Young Investigator Award Abstracts2023-10-31

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

HemaSphere2023-08-01

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

HemaSphere2023-08-01

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

2023-07-1032 citations

An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment

Hematological Oncology2023-06-013 citations

Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.

Journal of Clinical Oncology2023-01-249 citations

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood2022-11-153 citations

635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer

Regular and Young Investigator Award Abstracts2022-11-011 citations

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

HemaSphere2022-10-01

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

HemaSphere2022-10-01

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.

Journal of Clinical Oncology2022-06-0120 citations

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

Journal of Clinical Oncology2022-06-015 citations

10 more papers not shown

Favezelimab

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers